Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease

Joseph H. Antin; Allen R. Chen; Daniel R. Couriel; Vincent T. Ho; Richard A. Nash; Daniel Weisdorf

doi:10.1016/j.bbmt.2004.07.007

Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease

Joseph H. Antin, Allen R. Chen, Daniel R. Couriel, Vincent T. Ho, Richard A. Nash, Daniel Weisdorf

Research output: Contribution to journal › Review article › peer-review

65 Scopus citations

Abstract

Despite initial encouraging results, preliminary results showed no significant differences in response between the MP and MP plus infliximab groups. In the M.D. Anderson phase III experience, the incidence of infection and causative organisms were similar in both groups, although an increased risk of fungalinfections has been recently reported, and cautious use of this agent should probably include antifungalprophyl axis [100]. Despite encouraging response rates in the steroid-refractory setting, treatment of acute GVHD at an earlier stage with infliximab did not prove more effective than steroids alone. Once established, GVHD continues to be the main cause of death.

Original language	English (US)
Pages (from-to)	655-668
Number of pages	14
Journal	Biology of Blood and Marrow Transplantation
Volume	10
Issue number	10
DOIs	https://doi.org/10.1016/j.bbmt.2004.07.007
State	Published - Oct 2004

Bibliographical note

Funding Information:
This work was supported by grant nos. HL070149, CA18029, and HL36444 from the National Institutes of Health (Bethesda, MD).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.bbmt.2004.07.007

Find It

Find It at U of M Libraries

Cite this

@article{3f94e1c15c1945d8bb6abe65c2c25843,

title = "Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease",

abstract = "Despite initial encouraging results, preliminary results showed no significant differences in response between the MP and MP plus infliximab groups. In the M.D. Anderson phase III experience, the incidence of infection and causative organisms were similar in both groups, although an increased risk of fungalinfections has been recently reported, and cautious use of this agent should probably include antifungalprophyl axis [100]. Despite encouraging response rates in the steroid-refractory setting, treatment of acute GVHD at an earlier stage with infliximab did not prove more effective than steroids alone. Once established, GVHD continues to be the main cause of death.",

author = "Antin, {Joseph H.} and Chen, {Allen R.} and Couriel, {Daniel R.} and Ho, {Vincent T.} and Nash, {Richard A.} and Daniel Weisdorf",

note = "Funding Information: This work was supported by grant nos. HL070149, CA18029, and HL36444 from the National Institutes of Health (Bethesda, MD).",

year = "2004",

month = oct,

doi = "10.1016/j.bbmt.2004.07.007",

language = "English (US)",

volume = "10",

pages = "655--668",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease

AU - Antin, Joseph H.

AU - Chen, Allen R.

AU - Couriel, Daniel R.

AU - Ho, Vincent T.

AU - Nash, Richard A.

AU - Weisdorf, Daniel

N1 - Funding Information: This work was supported by grant nos. HL070149, CA18029, and HL36444 from the National Institutes of Health (Bethesda, MD).

PY - 2004/10

Y1 - 2004/10

N2 - Despite initial encouraging results, preliminary results showed no significant differences in response between the MP and MP plus infliximab groups. In the M.D. Anderson phase III experience, the incidence of infection and causative organisms were similar in both groups, although an increased risk of fungalinfections has been recently reported, and cautious use of this agent should probably include antifungalprophyl axis [100]. Despite encouraging response rates in the steroid-refractory setting, treatment of acute GVHD at an earlier stage with infliximab did not prove more effective than steroids alone. Once established, GVHD continues to be the main cause of death.

AB - Despite initial encouraging results, preliminary results showed no significant differences in response between the MP and MP plus infliximab groups. In the M.D. Anderson phase III experience, the incidence of infection and causative organisms were similar in both groups, although an increased risk of fungalinfections has been recently reported, and cautious use of this agent should probably include antifungalprophyl axis [100]. Despite encouraging response rates in the steroid-refractory setting, treatment of acute GVHD at an earlier stage with infliximab did not prove more effective than steroids alone. Once established, GVHD continues to be the main cause of death.

UR - http://www.scopus.com/inward/record.url?scp=4644356472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644356472&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2004.07.007

DO - 10.1016/j.bbmt.2004.07.007

M3 - Review article

C2 - 15389432

AN - SCOPUS:4644356472

SN - 1083-8791

VL - 10

SP - 655

EP - 668

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 10

ER -

Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this